Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis

Journal of Infection and Chemotherapy

Volumn 17, Issue 5, 2011, Pages 678-685

  Yoshida, Koichiro ^a   Okimoto, Niro ^b   Kishimoto, Michihiro ^b   Fukano, Hiroshi ^c   Hara, Hiroki ^c   Yoneyama, Hirohide ^d   Moriya, Osamu ^e   Kawanishi, Masayoshi ^f,g   Kimura, Makoto ^h   Matsushima, Toshiharu ^c   Niki, Yoshihito ^a  

^a SHOWA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c Kurashiki Daiichi Hospital   (Japan)

^d Kasaoka Daiichi Hospital   (Japan)

^e Moriya Osamu Clinic   (Japan)

^f Kawanishi Naika Clinic   (Japan)

^g Kaneda Hospital   (Japan)

^h Kimura Clinic   (Japan)

Author keywords

Community acquired pneumonia; Monte Carlo simulation; Moxifloxacin; Pharmacokinetics pharmacodynamics; Respiratory quinolone

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; C REACTIVE PROTEIN; CEFCAPENE; CLARITHROMYCIN; GARENOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL GROWTH; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROBACTER CLOACAE; FEMALE; GROWTH INHIBITION; HAEMOPHILUS INFLUENZAE; HOSPITAL PATIENT; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; NONHUMAN; OUTPATIENT; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SPUTUM CULTURE; STEADY STATE; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT DURATION; TROUGH PLASMA LEVEL;

EID: 84855424698     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0282-6     Document Type: Article

References (22)

1. Welte T, Petermann W, Schuermann D, Bauer TT, Reimnitz P, MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis. 2005;41:1697-705. (Pubitemid 41759850)
2. Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J. Efficacy of moxifloxacin for treatment of penicillin-, macrolide-and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia. Int J Clin Pract. 2005;59: 1253-9. (Pubitemid 43904492)
3. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH. Community-acquired pneumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis. 2006;42:73-81. (Pubitemid 41832083)
4. Torres A, Garau J, Arvis P, Arvis P, Carlet J, Choudhri S, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: The MOTIV study-a randomized clinical trial. Clin Infect Dis. 2008;46:1499-509. (Pubitemid 351706729)
5. Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H, The German Lung Abscess Study Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection. 2008;36:23-30.
6. Kobayashi H, Aoki N, Niki Y, Watanabe A, Kawai S, Odagiri S, et al. Phase III clinical study of BAY 12-8039 (moxifloxacin) for respiratory tract infections. Jpn J Chemother. 2005;53(S-3): 47-59. (in Japanese; abstract in English). (Pubitemid 43056137)
7. Kobayashi H, Aoki N, Niki Y, Watanabe A, Kawai S, Odagiri S, et al. Phase III double-blind comparative study of BAY 12-8039 (moxifloxacin) versus levofloxacin in patients with communityacquired pneumonia. Jpn J Chemother. 2005;53(S-3):27-46. (Pubitemid 43056136)
8. Aoki N. Respiratory tract infection-pneumonia. The Japanese Association for Infectious Disease, Japanese Society of Chemotherapy. Guidelines for the use of antimicrobial agents. Tokyo: Kyowakikaku; 2005. p. 106-121.
9. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J Infect Chemother. 1999;5:110-23. (Pubitemid 29317936)
10. Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: General view of the pathogens' antibacterial susceptibility. J Infect Chemother. 2009;15:156-67.
11. Madaras-Kelly KJ, Demasters TA. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000;37:253-60.
12. Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherpy. 2000; 46(Suppl 1):6-14. (Pubitemid 30248885)
13. Lacy MK, Lu W, Xu X, Tessier PR, Nicolau DP, Quintiliani R, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 1999;43:672-7. (Pubitemid 29109538)
14. Craig WA. Does dose matter? Clin Infect Dis. 2001;33(Suppl 3):S233-7.
15. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents. 2002;19:261-8. (Pubitemid 34308974)
16. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharamcodynamics of levofloxacin. J Am Med Assoc. 1998;279:125-9.
17. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodymanics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45:2793-7. (Pubitemid 32906673)
18. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37: 1073-81. (Pubitemid 23141323)
19. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589-96. (Pubitemid 34960355)
20. Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest. 2004;125:965-73. (Pubitemid 38367287)
21. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibreoptic bronchoscopy. J Antimicrob Chemother. 1999;44:835-8.
22. Breilh D, Jougon J, Djabarouti S, Gordien JB, Xuereb F, Velly JF, et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J Chemother. 2003;15(6):558-62. (Pubitemid 38241404)